Evidence method
Level · gp.fundamentals.debt_to_revenue
334.45% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Mar 31, 2017
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-17-024566General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.84% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
17.83% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
78.20% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
125.29% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
55.26% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
12.63% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4.42% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.78% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 93.80%
- Current
- 334.45%
- Delta
- 240.65%
- Previous
- 3.55%
- Current
- 5.84%
- Delta
- 2.29%
- Previous
- 21.36%
- Current
- 17.83%
- Delta
- -3.53%
- Previous
- 68.53%
- Current
- 78.20%
- Delta
- 9.67%
- Previous
- 20.36%
- Current
- 125.29%
- Delta
- 104.94%
- Previous
- 62.07%
- Current
- 55.26%
- Delta
- -6.81%
- Previous
- 15.61%
- Current
- 12.63%
- Delta
- -2.98%
- Previous
- 2.26%
- Current
- 4.42%
- Delta
- 2.16%
- Previous
- 4.72%
- Current
- 3.78%
- Delta
- -0.93%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.